- Home
- ESRT vs FBRX Comparison
ESRT vs FBRX Comparison
Compare ESRT & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESRT | FBRX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.1M | 899.4M |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ESRT | FBRX |
|---|---|---|
| Price | $4.72 | $76.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $6.35 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $768,270,000.00 | $36,000.00 |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $4.61 | $10.18 |
| 52 Week High | $8.07 | $77.20 |
Technical Indicators
Market Signals| Indicator | ESRT | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 84.26 |
| Support Level | N/A | $26.58 |
| Resistance Level | $5.85 | $77.20 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | -0.03 | -1.62 |
| Stochastic Oscillator | 13.41 | 51.43 |
Price Performance
Historical ComparisonAbout ESRT Empire State Realty Trust Inc.
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.